What Doctors Don't Tell YouA drug for irritable bowel syndrome (IBS) which was linked to the deaths of at least five patients, within nine months of being licensed, may soon be back on the market.
A drug for irritable bowel syndrome (IBS) which was linked to the deaths of at least five patients, within nine months of being licensed, may soon be back on the market.
